Cetera Investment Advisers Acquires 3,173 Shares of Illumina, Inc. (NASDAQ:ILMN)

Key Points

• Cetera Investment Advisers increased its holdings in Illumina, Inc. by 13.7%, acquiring an additional 3,173 shares during the first quarter, bringing their total ownership to 26,280 shares worth $2,085,000.
• Insider trading activity shows CFO Ankur Dhingra bought 6,100 shares for approximately $495,381, raising his ownership stake by 32.44%.
• Analysts have varying price targets for Illumina, with consensus estimates setting a price target of $127.74 and the stock currently trading around $94.56.

Cetera Investment Advisers raised its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 13.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,280 shares of the life sciences company's stock after buying an additional 3,173 shares during the period. Cetera Investment Advisers' holdings in Illumina were worth $2,085,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ILMN. Capital World Investors boosted its position in Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after buying an additional 14,481,232 shares during the period. Brown Advisory Inc. boosted its position in Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after buying an additional 1,909,118 shares during the period. Assenagon Asset Management S.A. boosted its position in Illumina by 2,057.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after buying an additional 879,533 shares during the period. Spyglass Capital Management LLC purchased a new stake in shares of Illumina in the 4th quarter worth about $71,855,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Illumina in the 4th quarter worth about $50,577,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Performance

Shares of ILMN traded up $3.10 during mid-day trading on Tuesday, hitting $97.88. 464,468 shares of the company traded hands, compared to its average volume of 2,378,379. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a 50-day moving average price of $95.43 and a two-hundred day moving average price of $90.52. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The stock has a market cap of $15.04 billion, a price-to-earnings ratio of 12.39, a P/E/G ratio of 2.13 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's quarterly revenue was down 4.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.36 earnings per share. Equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ILMN. Scotiabank cut shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price for the company. in a research report on Friday, July 11th. Wall Street Zen lowered Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Robert W. Baird lifted their price target on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. Morgan Stanley lifted their price target on Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, August 4th. Finally, Stephens set a $110.00 price target on Illumina and gave the company an "overweight" rating in a research report on Monday, August 4th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $124.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.